April A Apfelbaum, Sangita Pal, Sarah W Lamson, Eric Morin, Georges Ayoub, Sher Bahadur, Jeromy DiGiacomo, Margaret M Cusick, Prem Prabhakar, Connor C Bossi, Sehee Oh, Hyesung Jeon, Jinhua Wang, Hong Yue, Yuan Xiong, Amy Cameron, Patrick Rechter, Quang-De Nguyen, Sara J. Buhrlage, Eric S Fischer, Michael J Eck, Keith L Ligon, Pratiti Bandopadhayay
{"title":"B020: FGFR抑制剂在儿童低级别胶质瘤中的临床前研究","authors":"April A Apfelbaum, Sangita Pal, Sarah W Lamson, Eric Morin, Georges Ayoub, Sher Bahadur, Jeromy DiGiacomo, Margaret M Cusick, Prem Prabhakar, Connor C Bossi, Sehee Oh, Hyesung Jeon, Jinhua Wang, Hong Yue, Yuan Xiong, Amy Cameron, Patrick Rechter, Quang-De Nguyen, Sara J. Buhrlage, Eric S Fischer, Michael J Eck, Keith L Ligon, Pratiti Bandopadhayay","doi":"10.1158/1538-7445.pediatric25-b020","DOIUrl":null,"url":null,"abstract":"Pediatric brain cancers are the leading cause of cancer-related deaths in children. We (and others) have reported that close to 10% of all pediatric gliomas, encompassing low-grade and high-grade gliomas, harbor recurrent drive alterations in Fibroblast Growth Factor Receptor proteins (FGFR). In pediatric low-grade gliomas FGFR1 alterations are the most common and occur as structural variants, including kinase duplications and fusion proteins, or kinase-activating single nucleotide variants. Recurrent FGFR1 alterations and the existence of multiple FDA-approved (for adult) pan-FGFR inhibitors represent an attractive therapeutic target for precision medicine approaches, however a challenge with FGFR inhibitors has been the toxicities associated with them and the lack of clinical trials in children. A major aim of this project is to identify the best preclinical FGFR inhibitor candidates for these patients. To address this, we have generated isogenic mouse and human neural stem cells models driven by FGFR1 and BRAF alterations found in pLGGS. We have found that these models grow independent of growth factor and form tumors in mice. The FGFR1-altered models exhibit sensitivity to MEK inhibitors. They also exhibit efficacy to panFGFR inhibitors in vitro and in vivo. We are currently testing the PK characteristics and blood brain barrier efficacy of all available FGFR inhibitors to inform the best candidate for early phase clinical trials. Overall, this project aims to perform preclinical testing using our novel isogenic models to determine a candidate FGFR inhibitor for patients with pLGGs. Citation Format: April A Apfelbaum, Sangita Pal, Sarah W Lamson, Eric Morin, Georges Ayoub, Sher Bahadur, Jeromy DiGiacomo, Margaret M Cusick, Prem Prabhakar, Connor C Bossi, Sehee Oh, Hyesung Jeon, Jinhua Wang, Hong Yue, Yuan Xiong, Amy Cameron, Patrick Rechter, Quang-De Nguyen, Sara J. Buhrlage, Eric S Fischer, Michael J Eck, Keith L Ligon, Pratiti Bandopadhayay. Preclinical investigation of FGFR inhibitors in pediatric low-grade gliomas [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Discovery and Innovation in Pediatric Cancer— From Biology to Breakthrough Therapies; 2025 Sep 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl_2): nr B020.","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":"44 1","pages":""},"PeriodicalIF":16.6000,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Abstract B020: Preclinical investigation of FGFR inhibitors in pediatric low-grade gliomas\",\"authors\":\"April A Apfelbaum, Sangita Pal, Sarah W Lamson, Eric Morin, Georges Ayoub, Sher Bahadur, Jeromy DiGiacomo, Margaret M Cusick, Prem Prabhakar, Connor C Bossi, Sehee Oh, Hyesung Jeon, Jinhua Wang, Hong Yue, Yuan Xiong, Amy Cameron, Patrick Rechter, Quang-De Nguyen, Sara J. Buhrlage, Eric S Fischer, Michael J Eck, Keith L Ligon, Pratiti Bandopadhayay\",\"doi\":\"10.1158/1538-7445.pediatric25-b020\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Pediatric brain cancers are the leading cause of cancer-related deaths in children. We (and others) have reported that close to 10% of all pediatric gliomas, encompassing low-grade and high-grade gliomas, harbor recurrent drive alterations in Fibroblast Growth Factor Receptor proteins (FGFR). In pediatric low-grade gliomas FGFR1 alterations are the most common and occur as structural variants, including kinase duplications and fusion proteins, or kinase-activating single nucleotide variants. Recurrent FGFR1 alterations and the existence of multiple FDA-approved (for adult) pan-FGFR inhibitors represent an attractive therapeutic target for precision medicine approaches, however a challenge with FGFR inhibitors has been the toxicities associated with them and the lack of clinical trials in children. A major aim of this project is to identify the best preclinical FGFR inhibitor candidates for these patients. To address this, we have generated isogenic mouse and human neural stem cells models driven by FGFR1 and BRAF alterations found in pLGGS. We have found that these models grow independent of growth factor and form tumors in mice. The FGFR1-altered models exhibit sensitivity to MEK inhibitors. They also exhibit efficacy to panFGFR inhibitors in vitro and in vivo. We are currently testing the PK characteristics and blood brain barrier efficacy of all available FGFR inhibitors to inform the best candidate for early phase clinical trials. Overall, this project aims to perform preclinical testing using our novel isogenic models to determine a candidate FGFR inhibitor for patients with pLGGs. Citation Format: April A Apfelbaum, Sangita Pal, Sarah W Lamson, Eric Morin, Georges Ayoub, Sher Bahadur, Jeromy DiGiacomo, Margaret M Cusick, Prem Prabhakar, Connor C Bossi, Sehee Oh, Hyesung Jeon, Jinhua Wang, Hong Yue, Yuan Xiong, Amy Cameron, Patrick Rechter, Quang-De Nguyen, Sara J. Buhrlage, Eric S Fischer, Michael J Eck, Keith L Ligon, Pratiti Bandopadhayay. Preclinical investigation of FGFR inhibitors in pediatric low-grade gliomas [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Discovery and Innovation in Pediatric Cancer— From Biology to Breakthrough Therapies; 2025 Sep 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl_2): nr B020.\",\"PeriodicalId\":9441,\"journal\":{\"name\":\"Cancer research\",\"volume\":\"44 1\",\"pages\":\"\"},\"PeriodicalIF\":16.6000,\"publicationDate\":\"2025-09-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1158/1538-7445.pediatric25-b020\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/1538-7445.pediatric25-b020","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
儿童脑癌是儿童癌症相关死亡的主要原因。我们(和其他人)报道了近10%的儿童胶质瘤,包括低级别和高级别胶质瘤,纤维母细胞生长因子受体蛋白(FGFR)有复发性驱动改变。在儿童低级别胶质瘤中,FGFR1的改变是最常见的,并以结构变异的形式出现,包括激酶复制和融合蛋白,或激酶激活的单核苷酸变异。复发性FGFR1改变和多种fda批准的(成人)泛FGFR抑制剂的存在代表了精准医学方法的一个有吸引力的治疗靶点,然而FGFR抑制剂的一个挑战是与它们相关的毒性和缺乏儿童临床试验。该项目的一个主要目的是为这些患者确定最佳的临床前FGFR抑制剂候选药物。为了解决这个问题,我们建立了由pLGGS中发现的FGFR1和BRAF改变驱动的等基因小鼠和人类神经干细胞模型。我们发现这些模型在不依赖生长因子的情况下生长并在小鼠体内形成肿瘤。fgfr1改变的模型对MEK抑制剂表现出敏感性。它们在体外和体内也对panFGFR抑制剂有效。我们目前正在测试所有可用的FGFR抑制剂的PK特性和血脑屏障功效,以告知早期临床试验的最佳候选药物。总体而言,该项目旨在使用我们的新型等基因模型进行临床前测试,以确定pLGGs患者的候选FGFR抑制剂。引文格式:April A Apfelbaum, Sangita Pal, Sarah W Lamson, Eric Morin, Georges Ayoub, Sher Bahadur, jerome DiGiacomo, Margaret M Cusick, Prem Prabhakar, Connor C Bossi, Sehee Oh, Hyesung Jeon,金花Wang, Yue Hong,熊媛,Amy Cameron, Patrick Rechter, Quang-De Nguyen, Sara J. Buhrlage, Eric S Fischer, Michael J Eck, Keith L Ligon, Pratiti Bandopadhayay。FGFR抑制剂治疗小儿低级别胶质瘤的临床前研究[摘要]。AACR癌症研究特别会议论文集:儿童癌症的发现和创新-从生物学到突破性疗法;2025年9月25日至28日;波士顿,MA。费城(PA): AACR;癌症研究2025;85(18_Suppl_2): nr B020。
Abstract B020: Preclinical investigation of FGFR inhibitors in pediatric low-grade gliomas
Pediatric brain cancers are the leading cause of cancer-related deaths in children. We (and others) have reported that close to 10% of all pediatric gliomas, encompassing low-grade and high-grade gliomas, harbor recurrent drive alterations in Fibroblast Growth Factor Receptor proteins (FGFR). In pediatric low-grade gliomas FGFR1 alterations are the most common and occur as structural variants, including kinase duplications and fusion proteins, or kinase-activating single nucleotide variants. Recurrent FGFR1 alterations and the existence of multiple FDA-approved (for adult) pan-FGFR inhibitors represent an attractive therapeutic target for precision medicine approaches, however a challenge with FGFR inhibitors has been the toxicities associated with them and the lack of clinical trials in children. A major aim of this project is to identify the best preclinical FGFR inhibitor candidates for these patients. To address this, we have generated isogenic mouse and human neural stem cells models driven by FGFR1 and BRAF alterations found in pLGGS. We have found that these models grow independent of growth factor and form tumors in mice. The FGFR1-altered models exhibit sensitivity to MEK inhibitors. They also exhibit efficacy to panFGFR inhibitors in vitro and in vivo. We are currently testing the PK characteristics and blood brain barrier efficacy of all available FGFR inhibitors to inform the best candidate for early phase clinical trials. Overall, this project aims to perform preclinical testing using our novel isogenic models to determine a candidate FGFR inhibitor for patients with pLGGs. Citation Format: April A Apfelbaum, Sangita Pal, Sarah W Lamson, Eric Morin, Georges Ayoub, Sher Bahadur, Jeromy DiGiacomo, Margaret M Cusick, Prem Prabhakar, Connor C Bossi, Sehee Oh, Hyesung Jeon, Jinhua Wang, Hong Yue, Yuan Xiong, Amy Cameron, Patrick Rechter, Quang-De Nguyen, Sara J. Buhrlage, Eric S Fischer, Michael J Eck, Keith L Ligon, Pratiti Bandopadhayay. Preclinical investigation of FGFR inhibitors in pediatric low-grade gliomas [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Discovery and Innovation in Pediatric Cancer— From Biology to Breakthrough Therapies; 2025 Sep 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl_2): nr B020.
期刊介绍:
Cancer Research, published by the American Association for Cancer Research (AACR), is a journal that focuses on impactful original studies, reviews, and opinion pieces relevant to the broad cancer research community. Manuscripts that present conceptual or technological advances leading to insights into cancer biology are particularly sought after. The journal also places emphasis on convergence science, which involves bridging multiple distinct areas of cancer research.
With primary subsections including Cancer Biology, Cancer Immunology, Cancer Metabolism and Molecular Mechanisms, Translational Cancer Biology, Cancer Landscapes, and Convergence Science, Cancer Research has a comprehensive scope. It is published twice a month and has one volume per year, with a print ISSN of 0008-5472 and an online ISSN of 1538-7445.
Cancer Research is abstracted and/or indexed in various databases and platforms, including BIOSIS Previews (R) Database, MEDLINE, Current Contents/Life Sciences, Current Contents/Clinical Medicine, Science Citation Index, Scopus, and Web of Science.